Kennedy Capital Management LLC Lowers Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Kennedy Capital Management LLC lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 221,321 shares of the biopharmaceutical company’s stock after selling 4,875 shares during the period. Kennedy Capital Management LLC owned about 0.38% of Vanda Pharmaceuticals worth $1,060,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of VNDA. Geode Capital Management LLC grew its holdings in Vanda Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock valued at $6,949,000 after purchasing an additional 24,483 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in Vanda Pharmaceuticals by 4.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock valued at $3,925,000 after acquiring an additional 38,449 shares during the period. Federated Hermes Inc. raised its position in Vanda Pharmaceuticals by 1.4% during the fourth quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company’s stock worth $3,481,000 after acquiring an additional 9,840 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Vanda Pharmaceuticals by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares in the last quarter. Finally, Monaco Asset Management SAM grew its position in shares of Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock valued at $1,879,000 after purchasing an additional 188,836 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st. StockNews.com started coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating on the stock.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average price of $4.46 per share, with a total value of $44,600.00. Following the purchase, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This represents a 0.43 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders purchased a total of 32,000 shares of company stock worth $151,180 in the last three months. 8.90% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Trading Up 5.6 %

NASDAQ:VNDA opened at $4.36 on Tuesday. The company has a market cap of $254.26 million, a P/E ratio of -13.63 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a twelve month low of $3.85 and a twelve month high of $6.75. The company’s 50-day moving average price is $4.62 and its 200-day moving average price is $4.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. On average, analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.